Literature DB >> 1979273

Effects of the 5-HT3 antagonist GR38032F (ondansetron) on benzodiazepine withdrawal in rats.

A J Goudie1, M J Leathley.   

Abstract

Effects of the 5-HT3 receptor antagonist GR38032F (ondansetron) on chlordiazepoxide withdrawal were assessed in rats which received chlordiazepoxide b.i.d. for 21 days at doses up to 40 mg/kg per injection. Withdrawal signs recorded were: body weight and food intake, which fell and then recovered over 9 days. Saline or GR38032F (1.0, 0.1 or 0.01 mg/kg) were administered b.i.d. during withdrawal. Clear withdrawal signs were seen in rats treated with saline after chronic chlordiazepoxide. However, GR38032F at 0.1 mg/kg reduced the severity of withdrawal. At 0.01 mg/kg GR38032F shortened withdrawal duration, but did not diminish peak withdrawal signs. At 1.0 mg/kg GR38032F, did not attenuate withdrawal signs at all. GR38032F (0.01-1.0 mg/kg) had no effect on ad lib food intake, therefore the attenuation of withdrawal was probably not simply due to stimulation of appetite. These data support recent claims that GR38032F attenuates benzodiazepine withdrawal, and they indicate that this effect shows an inverted U-shaped dose-response curve.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979273     DOI: 10.1016/0014-2999(90)90638-m

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

2.  Ondansetron does not prevent physical dependence in patients taking opioid medications chronically for pain control.

Authors:  Larry F Chu; Tom Rico; Erika Cornell; Hannah Obasi; Ellen M Encisco; Haley Vertelney; Jamison G Gamble; Clayton W Crawford; John Sun; Anna Clemenson; Matthew J Erlendson; Robin Okada; Ian Carroll; J David Clark
Journal:  Drug Alcohol Depend       Date:  2017-08-14       Impact factor: 4.492

3.  Evaluation of the dependence potential of the selective 5-H1A agonist ipsapirone in rats and of its effects on benzodiazepine withdrawal.

Authors:  A J Goudie; M J Leathley
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 4.  5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions.

Authors:  J E Barrett; K E Vanover
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 5.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

6.  Effects of the CCKB antagonist L-365, 260 on benzodiazepine withdrawal-induced hypophagia in rats.

Authors:  A J Goudie; M J Leathley
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

7.  Are there changes in sensitivity to 5-HT3 receptor ligands following chronic diazepam treatment?

Authors:  N Andrews; S E File
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 8.  Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse.

Authors:  R M Hagan; G J Kilpatrick; M B Tyers
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Effects of the 5-HT3 antagonist ondansetron on benzodiazepine-induced operant behavioural dependence in rats.

Authors:  A J Goudie; M J Leathley
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Effects of 5-HT3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal.

Authors:  G A Higgins; P Nguyen; N Joharchi; E M Sellers
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.